You are here

PREMIUM

AstraZeneca's immunotherapy drug wins key lung cancer approval

BT_20180219_NVASTRA19Y9SP_3313602.jpg
The approval for AstraZeneca's immunotherapy drug opens up a multibillion-dollar market for a medicine that has until now lagged behind competitors.

London

ASTRAZENECA'S immunotherapy drug Imfinzi has won crucial approval from US regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

The US Food and Drug Administration said late on Friday that it...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes